Search Results - "Hoeger, Christopher W"
-
1
Cardiotoxicity of Anthracyclines
Published in Cardiology clinics (01-02-2025)“…Anthracycline chemotherapy is associated with cardiotoxicity, predominantly manifesting as left ventricular systolic dysfunction within the first year of…”
Get full text
Journal Article -
2
Doxorubicin Cardiotoxicity: Pathophysiology Updates
Published in Current treatment options in cardiovascular medicine (01-11-2020)“…Purpose of review Doxorubicin has long been known to cause cardiotoxicity, yet our understanding of its pathophysiologic mechanisms remains incomplete. This…”
Get full text
Journal Article -
3
International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)
Published in Circulation (New York, N.Y.) (06-03-2018)“…BACKGROUND:Identification of people with hypertrophic cardiomyopathy (HCM) who are at risk of sudden cardiac death (SCD) and require a prophylactic implantable…”
Get full text
Journal Article -
4
Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer
Published in Cardiology clinics (01-11-2019)“…Cardiovascular effects of cancer therapies are of concern. Prediction, diagnosis, and management of cardiotoxicity is a challenge. Cardiovascular biomarkers…”
Get full text
Journal Article -
5
Myocardial Contraction Fraction Predicts Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy and Normal Ejection Fraction
Published in Journal of cardiac failure (01-06-2019)“…•Myocardial contraction fraction (MCF) is a novel parameter that can distinguish between pathologic and physiologic hypertrophy.•This prospective cohort study…”
Get full text
Journal Article -
6
EVALUATION OF MYOCARDIAL CONTRACTION FRACTION AS A MEASURE OF LEFT VENTRICULAR FUNCTION IN HYPERTROPHIC CARDIOMYOPATHY
Published in Journal of the American College of Cardiology (17-03-2015)“…Background: Current measures of left ventricular (LV) function in hypertrophic cardiomyopathy (HCM) are poor predictors of disease progression; however, as the…”
Get full text
Journal Article -
7
Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors
Published in JACC CardioOncology (01-12-2023)“…Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications. We sought to characterize the incidence and risk…”
Get full text
Journal Article -
8
Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score
Published in Journal of the American Heart Association (02-01-2024)“…Evidence guiding the pre-hematopoietic stem cell transplantation (HSCT) cardiovascular evaluation is limited. We sought to derive and validate a pre-HSCT score…”
Get full text
Journal Article -
9
-
10
Abstract 10429: When You Hear Hoofbeats, Think Zebras and Not Horses: A Case of Cardiac Tamponade Preceding the Diagnosis of Rheumatoid Arthritis
Published in Circulation (New York, N.Y.) (08-11-2022)“…IntroductionWe present a case of a 50 year-old man who presented with one week of chest discomfort and ECG consistent with pericarditis (Fig. 1A) complicated…”
Get full text
Journal Article -
11
Abstract 11672: A Case of Postpartum Seizure, Cardiac Arrest, and Shock
Published in Circulation (New York, N.Y.) (08-11-2022)“…Cardiogenic shock (CS) in the peripartum period is associated with significant morbidity and mortality. Treatment of CS by specialists in high-volume centers…”
Get full text
Journal Article -
12
Cardiovascular Events After Hematopoietic Stem Cell Transplant
Published in JACC CardioOncology (01-12-2023)Get full text
Journal Article -
13
Abstract 14938: Cardiovascular Risk Factors and Disease Are Associated With Long-Term but Not Short-Term Mortality in Patients Undergoing Hematopoietic Stem Cell Transplantation
Published in Circulation (New York, N.Y.) (19-11-2019)“…IntroductionHematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for many life-threatening cancers, non-malignant marrow disorders,…”
Get full text
Journal Article